Bupropion: pharmacology and therapeutic applications

References

• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin. Ther.27(11), 1685–1695 (2005).
   PubMed Web of Science ®Google Scholar
• Wellbutrin XL® Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC (2006).
   Google Scholar
• Zyban® Prescribing Information. GlaxoSmithKline, Research Triangle Park, NC (2006).
   Google Scholar
• Hsyu PH, Singh A, Giargiari TD et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J. Clin. Pharmacol.37(8), 737–743 (1997).
   PubMed Web of Science ®Google Scholar
• Findlay JW, Van Wyck Fleet J, Smith PG et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur. J. Clin. Pharmacol.21(2), 127–135 (1981).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Klein C, Meineke I et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics13(10), 619–626 (2003).
   PubMedGoogle Scholar
• Stewart JJ, Berkel HJ, Parish RC et al. Single-dose pharmacokinetics of bupropion in adolescents: effects of smoking status and gender. J. Clin. Pharmacol.41(7), 770–778 (2001).
   Google Scholar
• Faucette SR, Hawke RL, Lecluyse EL et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos.28(10), 1222–1230 (2000).
   PubMed Web of Science ®Google Scholar
• Faucette SR, Hawke RL, Shord SS et al. Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab. Dispos.29(8), 1123–1229 (2001).
   PubMed Web of Science ®Google Scholar
• Hesse LM, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics14(4), 225–238 (2004).
   PubMedGoogle Scholar
• Martin H, Beaune P, de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics9(3), 295–306 (1999).
   PubMedGoogle Scholar
• Miksys S, Lerman C, Shields PG et al. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology45(1), 122–132 (2003).
   PubMed Web of Science ®Google Scholar
• Gervot L, Rochat B, Gautier JC et al. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics9(3), 295–306 (1999).
   PubMedGoogle Scholar
• Lerman C, Shields PG, Wileyto EP et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics12(8), 627–634 (2002).
   PubMedGoogle Scholar
• Spiller HA, Ramoska EA, Krenzelok EP et al. Bupropion overdose: a 3-year multi-center retrospective analysis. Am. J. Emerg. Med.12(1), 43–45 (1994).
   PubMed Web of Science ®Google Scholar
• Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J. Emerg. Med.22(3), 235–239 (2002).
   PubMed Web of Science ®Google Scholar
• Lerman C, Shields PG, Wileyto EP et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol.22(5), 541–548 (2003).
   PubMed Web of Science ®Google Scholar
• Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J. Affect. Disord.51(3), 237–254 (1998).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Pradko JF, Croft HA et al. Prevalence of sexual dysfunction among newer antidepressants. J. Clin. Psychiatry63(4), 357–366 (2002).
   PubMed Web of Science ®Google Scholar
• Horne RL, Ferguson JM, Pope HG et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J. Clin. Psychiatry49(7), 262–266 (1988).
   PubMed Web of Science ®Google Scholar
• Johnston JA, Lineberry CG, Ascher JA et al. A 102-center prospective study of seizure in association with bupropion. J. Clin. Psychiatry52(11), 450–456 (1991).
   PubMed Web of Science ®Google Scholar
• Dunner DL, Zisook S, Billow AA et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J. Clin. Psychiatry59(7), 366–373 (1998).
   PubMed Web of Science ®Google Scholar
• Tutka P, Barczynski B, Wielosz M. Convulsant and anticonvulsant effects of bupropion in mice. Eur. J. Pharmacol.499(1–2), 117–120 (2004).
   PubMed Web of Science ®Google Scholar
• Tutka P, Mroz T, Klucha K et al. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res.64(1–2), 13–22 (2005).
   PubMed Web of Science ®Google Scholar
• Settle EC, Stahl SM, Batey SR et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin. Ther.21(3), 454–463 (1999).
   PubMed Web of Science ®Google Scholar
• Fava M, Rush AJ, Thase ME et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim. Care Companion J. Clin. Psychiatry7(3), 106–113 (2005).
   Google Scholar
• Reimherr FW, Cunningham LA, Batey SR et al. A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients Clin. Ther.20(3), 505–516 (1998).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Carey TS et al. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int. Clin. Psychopharmacol.20(2), 59–69 (2005).
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Lohr KN et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann. Intern. Med.143(6), 415–426 (2005).
   PubMed Web of Science ®Google Scholar
• Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl.)114(4), 559–565 (1994).
   PubMed Web of Science ®Google Scholar
• Davidson JR, Connor KM. Bupropion sustained release: a therapeutic overview. J. Clin. Psychiatry59(Suppl. 4), 25–31 (1998).
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A et al. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J. Toxicol. Clin. Toxicol.42(3), 277–285 (2004).
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Bhaumik DK et al. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry62(2), 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy25(10), 1378–1382 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J. Emerg. Med.27(2), 147–151 (2004).
   PubMed Web of Science ®Google Scholar
• Curry SC, Kashani JS, LoVecchio F et al. Intraventricular conduction delay after bupropion overdose. J. Emerg. Med.29(3), 299–305 (2005).
   PubMed Web of Science ®Google Scholar
• Paris PA, Saucier JR. ECG conduction delays associated with massive bupropion overdose. J. Toxicol. Clin. Toxicol.36(6), 595–598 (1998).
   PubMed Web of Science ®Google Scholar
• Wenger TL, Cohn JB, Bustrack J. Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients. J. Clin. Psychiatry44(5 Pt 2), 174–175 (1983).
   PubMed Web of Science ®Google Scholar
• Belson MG, Kelley TR. Bupropion exposures: clinical manifestations and medical outcome. J. Emerg. Med.23(3), 223–230 (2002).
   PubMed Web of Science ®Google Scholar
• Lang T, Klein K, Fischer J et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics11(5), 399–415 (2001).
   PubMedGoogle Scholar
• Turpeinen M, Nieminen R, Juntunen T et al. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.Drug Metab. Dispos.32(6), 626–631 (2004).
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Tolonen A, Uusitalo J et al. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Ther.77(6), 553–559 (2005).
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Brauer LH, Tracy TS et al. Inhibition of CYP2D6 activity by bupropion. J. Clin. Psychopharmacol.25(3), 226–229 (2005).
   PubMed Web of Science ®Google Scholar
• Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther. Drug Monit.24(3), 436–437 (2002).
   PubMed Web of Science ®Google Scholar
• Weintraub D. Nortriptyline toxicity secondary to interaction with bupropion sustained-release. Depress Anxiety.13(1), 50–52 (2001).
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, Court MH et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos.28(10), 1176–1183 (2000).
   PubMed Web of Science ®Google Scholar
• Bertelsen KM, Venkatakrishnan K, Von Moltke LL et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos.31(3), 289–293 (2003).
   PubMed Web of Science ®Google Scholar
• Diamond S, Pepper BJ, Diamond ML et al. Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. Neurology51(1), 274–276 (1998).
   PubMed Web of Science ®Google Scholar
• Weiner LA, Smythe M, Cisek J. Serotonin syndrome secondary to phenelzine-venlafaxine interaction. Pharmacotherapy18(2), 399–403 (1998).
   PubMed Web of Science ®Google Scholar
• Graber MA, Hoehns TB, Perry PJ. Sertraline-phenelzine drug interaction: a serotonin syndrome reaction. Ann. Pharmacother.28(6), 732–735 (1994).
   PubMed Web of Science ®Google Scholar
• Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur. Psychiatry18(5), 264–265 (2003).
   PubMed Web of Science ®Google Scholar
• Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin. Pharm.12(3), 222–225 (1993).
   PubMedGoogle Scholar
• Kaplan LM. Pharmacological therapies for obesity. Gastroenterol. Clin. North Am.34(1), 91–104 (2005).
   PubMed Web of Science ®Google Scholar
• Griffith JD, Carranza J, Griffith C et al. Bupropion: clinical assay for amphetamine-like abuse potential. J. Clin. Psychiatry44, 206–208 (1983).
   PubMed Web of Science ®Google Scholar
• Musso DL, Mehta NB, Soroko FE et al Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. Chirality5, 495–500 (1993).
   PubMed Web of Science ®Google Scholar
• Damaj MI, Carroll FI, Eaton JB et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol. Pharmacol.66(3), 675–682 (2004).
   PubMed Web of Science ®Google Scholar
• Soroko FE, Mehta NB, Maxwell RM et al. Bupropion hydrochloride ((+/-) α-t-butylamino-3-chloropropiophenone HCl), a novel antidepressant agent. J. Pharm. Pharmacol.29, 767–770 (1977).
   PubMed Web of Science ®Google Scholar
• Ferris RM, Beaman OJ. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic β-adrenergic, serotonergic (5-HT2), α2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology22, 1257–1267 (1983).
   PubMed Web of Science ®Google Scholar
• Eshleman AJ, Henningsen RA, Neve KA, et al. Release of dopamine via the human transporter, Mol. Pharmacol.45, 312 (1994).
   PubMed Web of Science ®Google Scholar
• Johnson RA, Eshleman AJ, Meyers T et al. [3H]substrate-and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux. Synapse30(1), 97–106 (1999).
   Web of Science ®Google Scholar
• Stahl SM, Pradko JF, Haight, BR et al. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim. Care Companion J. Clin. Psychiatry6, 159–166 (2004).
   Google Scholar
• Owens MJ, Knight DL, Nemeroff CB Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry50, 345–350 (2001).
   PubMed Web of Science ®Google Scholar
• Cryan JF, O’Leary OF, Jin SH et al. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl Acad. Sci. USA101, 8186–8191 (2004).
   PubMed Web of Science ®Google Scholar
• Meyer JH, Goulding VS, Wilson AA et al. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berl.)163, 102–105 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer JH, Wilson AA, Sagrati S et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psychiatry161, 826–835 (2004).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS et al. Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of “high”. J. Pharmacol. Exp. Ther.288, 14–20 (1999).
   PubMed Web of Science ®Google Scholar
• Bondarev ML, Bondareva TS, Young R. et al. Behavioral and biochemical investigations of bupropion metabolites. Eur. J. Pharmacol.474, 85–93 (2003).
   PubMed Web of Science ®Google Scholar
• Martin P, Massol J, Colin JN et al. Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry23(4), 187–194 (1990).
   PubMed Web of Science ®Google Scholar
• Perumal AS, Smith Tm, Suckow RF. Effect of plasma from patients containing bupropion and its metabolites on the uptake of norepinephrine. Neuropharmacology25, 199–202 (1986).
   PubMed Web of Science ®Google Scholar
• Little JT, Ketter TA, Mathe AA et al. Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression. Biol. Psychiatry45(3), 285–289 (1999).
   PubMed Web of Science ®Google Scholar
• Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin), evidence for selective blockade of dopamine uptake in vivo.J. Pharmacol. Exp. Ther.215, 127–134 (1980).
   PubMed Web of Science ®Google Scholar
• Ascher JA, Cole JO, Colin JN et al. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry56, 395– 401(1995).
   PubMed Web of Science ®Google Scholar
• Cooper BR, Wang CM, Cox RF et al. Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology11, 133–141 (1994).
   PubMed Web of Science ®Google Scholar
• Dong J, Blier P. Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl.)155(1), 52–57 (2001).
   PubMed Web of Science ®Google Scholar
• Golden RN, Rudorfer MV, Sherer MA et al. Bupropion in depression. I. Biochemical effects and clinical response. Arch. Gen. Psychiatry45, 139–143 (1988).
   PubMed Web of Science ®Google Scholar
• Rau KS, Birdsall E, Hanson JE et al. Bupropion increases striatal vesicular monoamine transport. Neuropharmacology49(6), 820–830 (2005).
   PubMed Web of Science ®Google Scholar
• Colliver TL, Pyott SJ, Achalabun M et al. VMAT-2-Mediated changes in quantal size and vesicular volume. J. Neurosci.20(14), 5276–5282 (2000).
   PubMed Web of Science ®Google Scholar
• Harris L, Kimura Y, Shaikh NA. Phospholipase inhibition and the electrophysiology of acute ischemia: studies with amiodarone. J. Mol. Cell Cardiol.25(9), 1075–1090 (1993).
   PubMed Web of Science ®Google Scholar
• Haikerwal D, Dart AM, Little PJ et al. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J. Pharmacol. Exp. Ther.288(2), 834–837 (1999).
   PubMed Web of Science ®Google Scholar
• Odelola AT. More on amiodarone-induced depression. Br. J. Psychiatry175, 590–591 (1999).
   PubMed Web of Science ®Google Scholar
• Truong JG, Newman AH, Hanson GR et al. Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur. J. Pharmacol.504(1–2), 27–32 (2004).
   PubMed Web of Science ®Google Scholar
• Truong JG, Hanson GR, Fleckenstein AE. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. Eur. J. Pharmacol.492(2–3), 143–147 (2004).
   PubMed Web of Science ®Google Scholar
• Hanson GR, Sandoval V, Riddle E et al. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Ann. NY Acad. Sci.1025, 146–150 (2004).
   PubMed Web of Science ®Google Scholar
• Bechara A, Bertolino MV, Casabe A et al. A double-blind randomized placebo control study comparing the objective and subjective changes in female sexual response using sublingual apomorphine. J. Sex Med.1(2), 209–214 (2004).
   PubMed Web of Science ®Google Scholar
• Klos KJ, Bower JH, Josephs KA et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat. Disord.11(6), 381–386 (2005).
   PubMed Web of Science ®Google Scholar
• O’Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson’s disease. Mov. Disord.13(3), 536–539 (1998).
   PubMed Web of Science ®Google Scholar
• Courty E, Durif F, Zenut M et al. Psychiatric and sexual disorders induced by apomorphine in Parkinson’s disease. Clin. Neuropharmacol.20(2), 140–147 (1997).
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am. J. Psychiatry161(3), 564–566 (2004).
   PubMed Web of Science ®Google Scholar
• Cordeiro ML, Gundersen CB, Umbach JA. Lithium ions modulate the expression of VMAT-22 in rat brain. Brain Res.953(1–2), 189–194 (2002).
   PubMed Web of Science ®Google Scholar
• Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp.295, 321–327 (2000).
   PubMed Web of Science ®Google Scholar
• Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther.288, 88–92 (1999).
   PubMed Web of Science ®Google Scholar
• Miller DK, Sumithran SP, Dwoskin LP. Bupropion inhibits nicotine-evoked [3H]overflow from rat striatal slices preloaded with [3H]dopamine and from rat hippocampal slices preloaded with [3H]norepinephrine. J. Pharmacol. Exp. Ther.302, 1113–1122 (2002).
   PubMed Web of Science ®Google Scholar
• Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict. Biol.10, 219–231 (2005).
   PubMed Web of Science ®Google Scholar
• Feighner JP, Meredith CH, Stern WC et al. A double-blind study of bupropion and placebo in depression. Am. J. Psychiatry141(4), 525–529 (1984).
   PubMed Web of Science ®Google Scholar
• Zung WW. Review of placebo-controlled trials with bupropion. J. Clin. Psychiatry44(5 Pt 2), 104–114 (1983).
   PubMed Web of Science ®Google Scholar
• Fabre LF, Brodie HK, Garver D et al. A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. J. Clin. Psychiatry44(5 Pt 2), 88–94 (1983).
   PubMed Web of Science ®Google Scholar
• Halaris AE, Stern WC, Van Wyck Fleet J et al. Evaluation of the safety and efficacy of bupropion in depression. J. Clin. Psychiatry44(5 Pt 2), 101–103 (1983).
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Antidepressant response and plasma concentrations of bupropion. J. Clin. Psychiatry44(5 Pt 2), 137–139 (1983).
   PubMed Web of Science ®Google Scholar
• Johnston JA, Fiedler-Kelly J, Glover ED et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob. Res.3(2), 131–140 (2001).
   PubMedGoogle Scholar
• Murphy GE, Simons AD, Wetzel RD. Plasma nortriptyline and clinical response in depression. J. Affect. Disord.8(2), 123–129 (1985).
   PubMed Web of Science ®Google Scholar
• Weihs KL, Houser TL, Batey SR et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol. Psychiatry51(9), 753–761 (2002).
   PubMed Web of Science ®Google Scholar
• Zajecka JM. Clinical issues in long-term treatment with antidepressants. J. Clin. Psychiatry61(Suppl. 2), 20–25 (2000).
   PubMed Web of Science ®Google Scholar
• Weisler RH, Johnston JA, Lineberry CG et al. Comparison of bupropion and trazodone for the treatment of major depression. J. Clin. Psychopharmacol.14(3), 170–179 (1994).
   PubMed Web of Science ®Google Scholar
• Feighner J, Hendrickson G, Miller L et al. Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder. J. Clin. Psychopharmacol.6(1), 27–32 (1986).
   PubMed Web of Science ®Google Scholar
• Mendels J, Amin MM, Chouinard G et al. A comparative study of bupropion and amitriptyline in depressed outpatients. J. Clin. Psychiatry44(5 Pt 2), 118–120 (1983).
   PubMed Web of Science ®Google Scholar
• Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J. Clin. Psychiatry44(5 Pt 2), 121–129 (1983).
   PubMed Web of Science ®Google Scholar
• Branconnier RJ, Cole JO, Ghazvinian S et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J. Clin. Psychiatry44(5 Pt 2), 130–133 (1983).
   PubMed Web of Science ®Google Scholar
• Kavoussi RJ, Segraves RT, Hughes AR et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J. Clin. Psychiatry58(12), 532–537 (1997).
   PubMed Web of Science ®Google Scholar
• Feighner JP, Gardner EA, Johnston JA et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J. Clin. Psychiatry.52(8), 329–335 (1991).
   PubMed Web of Science ®Google Scholar
• Weihs KL, Settle EC Jr, Batey SR et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J. Clin. Psychiatry61(3), 196–202 (2000).
   PubMed Web of Science ®Google Scholar
• Zimmerman M, Posternak MA, Attiullah N et al. Why isn’t bupropion the most frequently prescribed antidepressant? J. Clin. Psychiatry66(5), 603–610 (2005).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Carmody TJ et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology25(1), 131–138 (2001).
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Katz J, Gitlin MJ. Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain. Neurology65(12 Suppl. 4), S7–S19 (20052005).
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA287(14), 1840–1870 (20022002).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med.354(12), 1231–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med.354(12), 1243–1252 (2006).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Clayton AH, Warnock JK, Kornstein SG et al. A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J. Clin. Psychiatry.65(1), 62–67 (2004).
   PubMed Web of Science ®Google Scholar
• Zisook S, Rush AJ, Haight BR et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol. Psychiatry59(3), 203–210 (2006).
   PubMed Web of Science ®Google Scholar
• Rojo JE, Ros S, Aguera L et al. Combined antidepressants: clinical experience. Acta. Psychiatr. Scand.36(Suppl. 428), 25–31 (2005).
   Google Scholar
• Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am. J. Psychiatry163(2), 232–239 (2006).
   PubMed Web of Science ®Google Scholar
• Nonacs RM, Soares CN, Viguera AC et al. Bupropion SR for the treatment of postpartum depression: a pilot study. Int. J. Neuropsychopharmacol.8(3), 445–449 (2005).
   PubMed Web of Science ®Google Scholar
• Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf.28(2), 137–152 (2005).
   Google Scholar
• Chun-Fai-Chan B, Koren G, Fayez I et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am. J. Obstet. Gynecol.192(3), 932–936 (2005).
   PubMed Web of Science ®Google Scholar
• Raison CL, Broadwell SD, Borisov AS et al. Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C. Brain Behav. Immun.19(1), 23–27 (2005).
   PubMed Web of Science ®Google Scholar
• Modell JG, Rosenthal NE, Harriett AE et al. Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL. Biol. Psychiatry58(8), 658–667 (2005).
   PubMed Web of Science ®Google Scholar
• Wileyto EP, Patterson F, Niaura R. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob. Res.7, 257–268 (2005).
   PubMed Web of Science ®Google Scholar
• Zellweger JP, Boelcskei PL, Carrozzi L et al. Bupropion SR vs placebo for smoking cessation in health care professionals. Am. J. Health Behav.29, 240–249 (2005).
   PubMed Web of Science ®Google Scholar
• Myles PS, Leslie K, Angliss M et al. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. Anaesthesia59, 1053–1058 (2004).
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Tonstad S, Hjalmarson A. et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J. Intern. Med.254, 184–192 (2003).
   PubMed Web of Science ®Google Scholar
• Killen JD, Robinson TN, Ammerman S et al. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J. Consult Clin. Psychol.72, 729–735 (2004).
   PubMed Web of Science ®Google Scholar
• Simon JA, Duncan C, Carmody TP et al. Bupropion for smoking cessation: a randomized Trial. Arch. Intern. Med.164, 1797–1803 (2004).
   PubMedGoogle Scholar
• Cox LS, Patten CA, Niaura RS et al. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J. Gen. Intern. Med.19, 828–834 (2004).
   PubMed Web of Science ®Google Scholar
• Lerman C, Niaura R, Collins BN et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol. Addict Behav.18, 362–366 (2004).
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Leischow SJ, Nides MA et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med.340, 685–691 (1999).
   PubMed Web of Science ®Google Scholar
• Haggstram FM, Chatkin JM, Sussenbach-Vaz E et al..A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulm. Pharmacol. Ther.19(3), 205–209 (2006).
   PubMed Web of Science ®Google Scholar
• Hatsukami DK, Rennard S, Patel MK et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. Am. J. Med.116(3), 151–157 (2004).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Solvason B, Poirier J et al. A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction. J. Clin. Psychiatry66(7), 844–848 (2005).
   PubMed Web of Science ®Google Scholar
• Segraves RT, Clayton A, Croft H et al. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol.24(3), 339–342 (2004).
   PubMed Web of Science ®Google Scholar
• Newton TF, Roache JD, De La Garza R et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology31(7), 1537–1544 (2005).
   PubMed Web of Science ®Google Scholar
• Dannon PN, Lowengrub K, Musin E et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J. Clin. Psychopharmacol.25(6), 593–596 (2005).
   PubMed Web of Science ®Google Scholar
• Corcoran C, Wong ML, O’Keane V. Bupropion in the management of apathy. J. Psychopharmacol.18(1), 133–135 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM et al. Bupropion may improve restless legs syndrome: a report of three cases. Clin. Neuropharmacol.28(6), 298–301 (2005).
   PubMed Web of Science ®Google Scholar
• Yang C, White DP, Winkelman JW. Antidepressants and periodic leg movements of sleep. Biol. Psychiatry58(6), 510–514 (2005).
   PubMed Web of Science ®Google Scholar
• Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol.6(5), 262–276 (2005).
   PubMedGoogle Scholar
• Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology57, 1583–1588 (2001).
   PubMed Web of Science ®Google Scholar
• Moss EL, Simpson JS, Pelletier G et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psycho-oncology15(3), 259–267 (2005).
   Web of Science ®Google Scholar
• Cullum JL, Wojciechowski AE, Pelletier G et al. Bupropion sustained release treatment reduces fatigue in cancer patients. Can. J. Psychiatry49(2), 139–44 (2004).
   PubMed Web of Science ®Google Scholar
• Marin H, Menza MA. The management of fatigue in depressed patients. Essent Psychopharmacol.6(4), 185–192 (2005).
   PubMedGoogle Scholar
• Kast RE, Altschuler EL. Bupropion and chronic aphthous ulceration. Arch. Dermatol.141(9), 1167 (2005).
   PubMedGoogle Scholar
• Kast RE, Altschuler EL. Remission of Crohn’s disease on bupropion. Gastroenterology121(5), 1260–1261 (2001).
   PubMed Web of Science ®Google Scholar
• Kane S, Altschuler EL, Kast RE. Crohn’s disease remission on bupropion. Gastroenterology125(4), 1290 (2003).
   PubMed Web of Science ®Google Scholar
• Kast RE. Evidence of a mechanism by which etanercept increased TNF-α in multiple myeloma: new insights into the biology of TNF-α giving new treatment opportunities-the role of bupropion. Leuk. Res.29(12), 1459–1463 (2005).
   PubMed Web of Science ®Google Scholar
• Kast RE, Altschuler EL. Anti-apoptosis function of TNF-α in chronic lymphocytic leukemia: lessons from Crohn’s disease and the therapeutic potential of bupropion to lower TNF-α. Arch. Immunol. Ther. Exp.53(2), 143–147 (2005).
   PubMed Web of Science ®Google Scholar
• Brustolim D, Riberio-dos-Santos R, Kast RE et al. A new chapter opens in anti-inflammatory treatment: Bupropion lowers TNF-α and interferon-γ in mice. accepted for publication. Int. Immunopharm. (2006) (Epub ahead of print).
   Google Scholar
• Kast RE, Altschuler EL. Tumor necrosis factor-α in hepatitis B: potential role for bupropion. J. Hepatol.39(1), 131–133 (2003).
   PubMed Web of Science ®Google Scholar
• Yu H, Rothman RB, Dersch CM et al. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg. Med. Chem.8, 2689–2692 (2000).
   PubMed Web of Science ®Google Scholar
• Cozzi NV, Sievert MK, Shulgin AT et al. Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Eur. J. Pharmacol.381, 63–69 (1999).
   PubMed Web of Science ®Google Scholar
• Foley K. Aminopropiophenones at the Norepinephrine Transporter: Structure-activity Relationships and Behavioral Effects of Methcathinone Analogs, In: Pharmacology. East Carolina University School of Medicine, Greenville, NC, USA (2002)
   Google Scholar